|Articles|April 1, 2004

Does it impact survival?

Washington - Sentinel lymph node biopsy may not be standard of care today in the management of patients with early melanoma and clinically negative nodes, but neither should it be considered an experimental technique, said Gary S. Rogers, M.D., at the annual meeting of the American Academy of Dermatology.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Latest CME